3 March 2016
DETAILS
Arkema: Full year 2015 results
• €7,683 million sales, +29% up on 2014 including
+26% related to changes in the scope of business
• €1,057 million EBITDA, significantly above full-year guidance,
and strongly up (+35%) over 2014 (€784 million)
• Very good growth of Bostik within the Group
(€183 million EBITDA over 12 months
versus €158 million in 2014).
As announced in September 2014, the acquisition is accretive
in earnings and cash from first year
• Significant contribution of internal growth projects to the results,
in particular of thiochemicals plant in Malaysia
• 13.8% EBITDA margin up year-on-year (13.2% in 2014)
despite Bostik dilutive effect of almost
half a percentage point
• €285 million net income Group share, +71% up
on 2014 (€167 million)
• €4.23 adjusted net income per share,
+14% up year-on-year
• Strong cash generation with
+€442 million free cash flow1
and €1,379 million net debt, with a gearing back at 35%
just one year after Bostik acquisition
• Proposed dividend increase to €1.90 per share
(€1.85 per share for 2014)
WWW.CHEMWINFO.COM BY KHUN PHICHAI
